Use of exhaled nitric oxide levels in predicting response to oral steroids in patients with COPD

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12605000683639

Enrollment

Registered

2005-10-21

Start date

2003-01-03

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Baseline exhaled nitric oxide levels are taken at the beginning of the study. 20mg Prednisone daily or placebo is given for 3 weeks in a cross-over design with a 4 week washout period.

Study design

Allocation

Randomised controlled trial

Intervention model

Crossover

Primary purpose

Treatment

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

40 Years to No maximum

Healthy volunteers

Inclusion criteria

Patients with COPDFEV1 <70% predicted, FEV1/FVC ratio <70%Smoker or ex-smoker of at least 20 pack years.

Exclusion criteria

Acute exacerbation within the last 3 months, patients receiving long-term oxygen treatment.

Outcome results